Pozen resubmits new drug application

Posted by Corinne Jurney on July 16, 2014 

Chapel Hill drugmaker Pozen announced Wednesday that federal regulators have accepted the resubmission of its new drug application for its heart attack and stroke-prevention pill.

Pozen was forced to resubmit its application after the U.S. Food and Drug Administration in April declined to approve the initial filing, citing deficiencies at a manufacturing facility where an active ingredient is produced. The announcement triggered a 10 percent one-day decline in Pozen’s stock.

The company said Wednesday it has since addressed the problem and refiled its application.

Pozen’s drug is an alternative to aspirin for treating heart-disease and stroke patients. Patients who have had strokes or heart disease are often prescribed aspirin to lower the risk of future complications, but taking traditional aspirin carries a high risk of stomach ulcers.

Pozen’s drug is a low-ulcer-risk aspirin that combines aspirin with instant-release of omeprazole. Omeprazole coats the stomach lining before the aspirin is released, minimizing the patient’s risk of developing ulcers.

The company’s application is for two doses of aspirin, 81 mg and 325 mg. Sanofi US is set to commercialize the product.

The FDA is expected to rule on the new application by December 30.

If approved, the drug will be Pozen’s third approved product in its portfolio. The company already markets the acute migraine treatment drug Treximet and arthritis relief drug Vimovo.

Pozen shares were down more than 6 percent mid-morning Wednesday to $8.26.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service